Abnormally Activated MNX1 Promotes Tumor Growth and Osimertinib Resistance and Predicts Survival in EGFR-Mutant Lung Adenocarcinoma
Weiguo Gu, Jinyu Gan, Penghui Liu, Jianfei Lai, Chaoxing Liu, Guohua Zhang, Chao Shi, Qingkun Jiang, Feng Qiu · 2025
Read Abnormally Activated MNX1 Promotes Tumor Growth and Osimertinib Resistance and Predicts Survival in EGFR-Mutant Lung Adenocarcinoma by Weiguo Gu, Jinyu Gan, Penghui Liu, Jianfei Lai, Chaoxing Liu, Guohua Zhang, Chao Shi, Qingkun Jiang, Feng Qiu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12732208.txt.
Description
Weiguo Gu and co-authors study a gene switch called MNX1 in lung cancer, in this 2025 paper. The cancer type they study carries a changed growth receptor and is treated with a drug that blocks it. Many tumors learn to resist that drug through side routes. Whether MNX1, a gene more known for nerve and pancreas growth, helps drive that resistance was unknown.
Data from tumor banks and tissue tests showed MNX1 switched on at high levels in these tumors. High levels tracked with poor survival and helped tell cancer from healthy tissue. In lab tests, active MNX1 made cells grow, invade, and resist the drug. Blocking MNX1 while giving the drug shrank tumors in mice and restored drug response. The authors propose MNX1 as both a warning marker and a target.
Catalog record
| CREATOR | Weiguo Gu, Jinyu Gan, Penghui Liu, Jianfei Lai, Chaoxing Liu, Guohua Zhang, Chao Shi, Qingkun Jiang, Feng Qiu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |